These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Dermatologic side effects induced by new angiogenesis inhibitors].
    Author: Sibaud V, Garrido-Stowhas I, Cottura E, Chevreau C.
    Journal: Bull Cancer; 2011 Oct; 98(10):1221-9. PubMed ID: 22001771.
    Abstract:
    While new anticancer angiogenesis inhibitors present a well-tolerated safety profile, they are not without adverse events. The signaling pathways and/or receptors inhibited by these new drugs are often physiologically expressed in the skin and/or hair follicle and cutaneous toxicity is on the forefront. This article reviews the main dermatologic adverse events induced by these targeted anticancer therapies with a partial or exclusive antiangiogenic activity: sorafenib, sunitinib, pazopanib, vandetanib, everolimus, temsirolimus or bevacizumab.
    [Abstract] [Full Text] [Related] [New Search]